Compare MFA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | SPRY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.0M | 946.0M |
| IPO Year | N/A | N/A |
| Metric | MFA | SPRY |
|---|---|---|
| Price | $9.67 | $10.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.96 | ★ $31.25 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 15.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $279,011,000.00 | $142,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | $124.59 |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $7.85 | $6.66 |
| 52 Week High | $11.08 | $18.90 |
| Indicator | MFA | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 56.11 |
| Support Level | $9.48 | $10.02 |
| Resistance Level | $9.72 | $11.45 |
| Average True Range (ATR) | 0.14 | 0.60 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 70.00 | 51.03 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.